User profiles for Eugeen Vanmechelen
Eugeen VanmechelenCSO, ADx NeuroSciences Verified email at adxneurosciences.com Cited by 24850 |
Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF
…, PD Mehta, K Iqbal, H Pottel, E Vanmechelen… - Neurology, 1999 - AAN Enterprises
Objective: To evaluate CSF levels of β-amyloid (1-42) (Aβ 42 ) alone and in combination with
CSF tau for distinguishing AD from other conditions. Methods: At 10 centers in Europe and …
CSF tau for distinguishing AD from other conditions. Methods: At 10 centers in Europe and …
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s
disease are needed to facilitate the initial screening process of participants in disease-…
disease are needed to facilitate the initial screening process of participants in disease-…
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring
Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the …
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the …
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
…, L Minthon, P Davidsson, E Vanmechelen… - Archives of …, 2001 - jamanetwork.com
Objective To evaluate the diagnostic potential of cerebrospinal fluid (CSF) levels of tau and
β-amyloid protein ending at amino acid 42 (Aβ42) as biomarkers for Alzheimer disease (AD) …
β-amyloid protein ending at amino acid 42 (Aβ42) as biomarkers for Alzheimer disease (AD) …
Cerebrospinal fluid β-amyloid (1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease
…, H Vanderstichele, E Vanmechelen… - Archives of …, 1999 - jamanetwork.com
Objectives To study the diagnostic potential of the 42 amino acid form of β-amyloid (β-amyloid
(1-42) ) in cerebrospinal fluid (CSF) as a biochemical marker for Alzheimer disease (AD), …
(1-42) ) in cerebrospinal fluid (CSF) as a biochemical marker for Alzheimer disease (AD), …
Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology
…, C Troakes, A Hye, S Gauthier, E Vanmechelen… - Acta …, 2021 - Springer
The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …
plasma, has shown great promise in detecting Alzheimer’s disease (AD) pathophysiology. Tau …
Detection of proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme‐linked immunosorbent assay
…, M Mercken, E Vanmechelen… - Journal of …, 1993 - Wiley Online Library
Alzheimer's disease is a progressive degenerative dementia characterized by the abundant
presence of neurofibrillary tangles in neurons. This study was designed to test whether the …
presence of neurofibrillary tangles in neurons. This study was designed to test whether the …
Measurement of phosphorylated tau epitopes in the differential diagnosisof Alzheimer disease: a comparative cerebrospinal fluid study
…, K Ishiguro, H Ohno, E Vanmechelen… - Archives of general …, 2004 - jamanetwork.com
Background Abnormal hyperphosphorylation of the microtubule-associated protein tau and
its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of …
its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of …
Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values
…, N Andreasen, P Davidsson, E Vanmechelen… - Clinical …, 2001 - academic.oup.com
Background: Tau protein and the 42-amino acid form of β-amyloid (Aβ42) measured in
cerebrospinal fluid (CSF) have been proposed as potential biochemical diagnostic markers for …
cerebrospinal fluid (CSF) have been proposed as potential biochemical diagnostic markers for …
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
…, P Davidsson, H Vanderstichele, E Vanmechelen… - Neuroscience …, 2001 - Elsevier
An increase in cerebrospinal fluid (CSF)-total-tau, and recently also in CSF-phospho-tau, has
been found in Alzheimer's disease (AD). However, the mechanisms for these changes are …
been found in Alzheimer's disease (AD). However, the mechanisms for these changes are …